Aqueous humour

Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough

Retrieved on: 
Wednesday, November 8, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, Invention, MD, Corneal transplantation, Cell, Aqueous humour, Surgeon, Kyoto Prefectural University of Medicine, Endothelium, Therapy, Patient, Pharmaceutical industry

Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.

Key Points: 
  • Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.
  • Its cell therapy procedure is accessible for ophthalmologists, involving a single administration into the anterior chamber of the patient’s eye.
  • Leveraging the pioneering inventions of Professor Shigeru Kinoshita, MD, of Kyoto Prefecture University of Medicine, Aurion Biotech has acquired the technology for further development.
  • “We are honored to be named BioTech Breakthrough’s ‘Regenerative Therapeutics Company of the Year,’” said Greg Kunst, Aurion Biotech’s CEO.

Heidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Retrieved on: 
Friday, October 13, 2023
Apps, Applications, Technology, Medical Devices, FDA, Health Technology, Software, Biotechnology, Hardware, Health, Optical, Diagnosis, Multimedia, Lumia imaging apps, Acquisition, Corneal topography, Aqueous humour, OD, OCT, Clinical trial, Cataract, Heidelberg, IOL, Tomography, Cornea, Medical device, Medical imaging, Telescopic sight

Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.

Key Points: 
  • Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.
  • View the full release here: https://www.businesswire.com/news/home/20231013216160/en/
    “Building upon our previous CE-marking, we are thrilled that the ANTERION platform is now available to eye care providers across the U.S.,” said Arianna Schoess Vargas, Managing Director of Heidelberg Engineering GmbH.
  • Central to the ANTERION platform is the Imaging App, which was FDA cleared in November 2021.
  • For more information about ANTERION, visit our website or contact us directly.

Precision Fermentation Fuels Growth in Ophthalmic Viscoelastic Devices Market: Opportunities and Key Segments - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Pressure, ASP, Strategic planning, COVID-19, Eye, OVD, Bacteria, Aqueous humour, Hurtigruten AS, Investment, Bioprocess, SWOT analysis, Growth, Meat, Melt, Forecast, Impossible Foods, Retail, Marketing, Telecommunications

This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.

Key Points: 
  • This report provides a comprehensive analysis of the Ophthalmic Viscoelastic Devices (OVD) market, highlighting key trends, market dynamics, and valuable insights for stakeholders.
  • Ophthalmic viscoelastic devices, commonly known as OVDs, play a crucial role in intraocular surgeries.
  • Regional Insights: The Asia Pacific region is expected to register the highest CAGR in the precision fermentation ingredients market.
  • Revenue Growth: Drive revenues by identifying market categories and segments offering maximum opportunities for consolidations, investments, and strategic partnerships.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023
Visio, Specialist, Presbyopia, Telecanthus, Patient, LASIK, Adjoint, Near-sightedness, ATLAS, ELANA, University, Corneal topography, University of Colorado, Cataract, Aqueous humour, LVC, Retina, Far-sightedness, Refractive surgery, AT, SLT, Eye, Iridectomy, Glaucoma, Surgeon, FEBO, Quality of life, SMILE, Pupillometry, Assistant professor, Astigmatism, European Society for Medical Oncology, Robotics, Visual acuity, Charles University, Telescopic sight, Medical imaging, Medical device, Ophthalmology, ZEISS, IOL

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

ZEISS advances cataract and corneal refractive surgical care with new workflow innovations

Retrieved on: 
Thursday, August 31, 2023
Visio, Specialist, Presbyopia, Telecanthus, Patient, LASIK, Adjoint, Near-sightedness, ATLAS, ELANA, University, Corneal topography, University of Colorado, Cataract, Aqueous humour, LVC, Retina, Far-sightedness, Refractive surgery, AT, SLT, Eye, Iridectomy, Glaucoma, Surgeon, FEBO, Quality of life, SMILE, Pupillometry, Assistant professor, Astigmatism, European Society for Medical Oncology, Robotics, Visual acuity, Charles University, Telescopic sight, Medical imaging, Medical device, Ophthalmology, ZEISS, IOL

JENA, Germany and DUBLIN, Calif., Aug. 31, 2023 /PRNewswire/ -- ZEISS Medical Technology will showcase new ophthalmic innovations within the cataract and corneal refractive workflows at the European Society of Cataract and Refractive Surgery (ESCRS) annual conference from Sept. 8-12, 2023, in Vienna, Austria. As part of the ZEISS Medical Ecosystem, the following enhancements bolster ZEISS's leadership position in ophthalmic diagnostic and surgical workflow solutions, continuing the company's transformative progress toward more fully integrated, data-driven healthcare:

Key Points: 
  • - New ZEISS ATLAS 500 combines corneal topography and dry eye assessment for improved decision making within the cataract and corneal refractive workflows.
  • "As we continue to extend our position in digital ophthalmic solutions, ZEISS is proud to unveil our latest workflow innovations that are helping to transform the way surgical care is practiced today.
  • Within the ZEISS Premium Cataract Workflow, cataract surgeons are now offered new cutting-edge technology to boost both clinical and commercial success.
  • The new ZEISS ATLAS 500 integrates into both the ZEISS corneal refractive and cataract workflows.

Palatin Technologies to Host Key Opinion Leader Webinar

Retrieved on: 
Monday, May 1, 2023
PTN, DED, KOL, Osteopathic medicine in the United States, Philadelphia College of Osteopathic Medicine, CMO, Trial of the century, Telecanthus, Ophthalmology, Aqueous humour, Patient, Bremelanotide, Webcast, Research, Conference, NYSE, New Orleans, Pharmaceutical industry, Palatine

CRANBURY, N.J., May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a key opinion leader (KOL) webinar on May 8, 2023 at 11:00 a.m. ET.

Key Points: 
  • - Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET
    CRANBURY, N.J., May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a key opinion leader (KOL) webinar on May 8, 2023 at 11:00 a.m.
  • The webinar will be moderated by Carl Spana, Ph.D., President & CEO of Palatin, and feature Bruce C. Stouch, Ph.D. (Philadelphia College of Osteopathic Medicine) and George Ousler, M.S.
  • The KOL presentation will be followed by a question-and-answer session with Dr. Stouch, Mr. Ousler, Dr. Raizman and Palatin senior management.
  • To register for the webinar and participate in the webcast, please go to Palatin's website at www.palatin.com or click here .

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Retrieved on: 
Monday, April 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Medical Devices, Inflammation, Infection, Tissue, TASS, Allergy, IOP, Cornea, Sodium, Surgeon, Use, Cataract, Eye, Clinical trial, Particulates, OVD, Decompensation, Sale, Direction, Aqueous humour, Intraocular pressure, Bausch & Lomb, Hurtigruten AS, Patient, Phacoemulsification, Freezing, Risk, Cannula, Radical (chemistry), Sorbitol, Paratriathlon, Regulation of tobacco by the U.S. Food and Drug Administration, IOL, NYSE, Posterior cerebral artery, Food, Veterinary medicine, Dentistry, Medical device, Birth control, Pharmaceutical industry, Dry cleaning

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.
  • TotalVisc Viscoelastic System includes both StableVisc and ClearVisc™, a dispersive OVD, and protects ocular tissue during the surgical procedure.
  • TotalVisc is the only dual pack in the United States that includes a dispersive and cohesive OVD formulated with sorbitol.
  • Federal (USA) law restricts this device to the sale by or on the order of a physician.

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Thursday, March 2, 2023
Retinal detachment, Geographic atrophy, Clinical trial, Research, Maintenance, Macula, AMD, CMS, Aqueous humour, Treatment, Patient, Cleveland Clinic, Marketing, Cleveland, Center for Medicare and Medicaid Innovation, CALM, Investment, Webcast, Paratriathlon, G&A, Retina, Therapy, Medicare, Enrollment, Cryptocurrency, Pharmaceutical industry, Video game, Reinsurance, Medicaid

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate developments.
  • Net product revenue for YUTIQ was $9.0 million in the fourth quarter of 2022 compared to $5.8 million for the fourth quarter ended December 31, 2021, a 55% increase.
  • Review of Results for the Fourth Quarter Ended December 31, 2022
    For the quarter ended December 31, 2022, total net revenue was $10.5 million compared to $11.5 million for the quarter ended December 31, 2021.
  • ET to discuss the results for the fourth quarter and year ended December 31, 2022 and recent corporate developments.

Oculis announces publication of positive Phase 2 data in Translational Vision Science & Technology (TVST) investigating topical anti-TNFα agent licaminlimab (OCS-02) in acute anterior uveitis

Retrieved on: 
Tuesday, November 22, 2022
Uveitis, DED, AAU, Severe cognitive impairment, Treatment, DME, Geographic atrophy, Inflammation, Antibody, Translational Vision Science & Technology, University, Glaucoma, ARVO, IOP, Risk, Physician, Diabetic retinopathy, Patient, Aqueous humour, Random phase approximation, AON, Disease, Swelling, Vision, Duane syndrome, NIH, Cataract, SUN, Mall of America, Pharmaceutical industry, AC, Ophthalmology, Pecten oculi

The study, Topical Ocular Anti-TNF Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study, is accessible on the National Institutes of Health (NIH) website here .

Key Points: 
  • The study, Topical Ocular Anti-TNF Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study, is accessible on the National Institutes of Health (NIH) website here .
  • Licaminlimab (OCS-02) was observed to be well tolerated, including no increase in intra-ocular pressure related to licaminlimab (OCS-02).
  • Licaminlimab (OCS-02) is an anti-TNF antibody product candidate based on an innovative antibody fragment technology allowing it to be administered topically.
  • Phase 2b clinical trials of licaminlimab (OCS-02) for the treatment of non-infectious anterior uveitis, as well as dry eye disease (DED), are currently being planned by Oculis.

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, November 2, 2022
ACT, OCT, Floater, GLOBE, Industry, COVID-19, Eye, Investment, Compliance, Private Securities Litigation Reform Act, Annual general meeting, Company, FDA, Webcast, Aqueous humour, ASRS, Visual inspection, CEO, Toxic leukoencephalopathy, Centers for Medicare & Medicaid Services, U.S. FDA, Șaeș, Nasdaq, CST, Cleveland, Safety, NASDAQ, Investor, U.S. Securities and Exchange Commission, Patient, Therapy, Endophthalmitis, Retinal detachment, Federal, Inflammation, Clinical trial, CMS, SAFE, AAO, Processor register, Center, CALM, Treatment, AMD, Intellectual property, Retina, Retinal vasculitis, Medicare, AxoGen, Cleveland Clinic, Visual acuity, Forward-looking statement, Pharmaceutical industry, Video game

WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate developments.

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the third quarter endedSeptember 30, 2022and highlighted recent corporate developments.
  • The first patient was dosed in the Phase 2 PAVIA clinical trial of EYP-1901 for the treatment of NPDR in September 2022.
  • In October 2022, the Company and ImprimisRx mutually terminated an agreement for the commercialization of DEXYCU effective December 31, 2022.
  • EyePoint will host a conference call today, at8:30 a.m. ETto discuss the results for the third quarter ended September 30, 2022 and recent corporate developments.